Clinical Trial

Teletherapy vs. In-Person Cognitive Behavioral Therapy for Generalized Anxiety Disorder

Study acronym: TIPCBT-GAD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 13, 2025 (before its estimated August 26, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this randomized controlled trial is to compare the clinical efficacy of teletherapy versus in-person third-wave cognitive behavioral therapy (CBT) in treating generalized anxiety disorder (GAD) among young individuals aged 18-45 years in Pakistan. The main questions it aims to answer are: * Is teletherapy as effective as in-person therapy in reducing anxiety symptoms and stress? * Do therapeutic alliance, treatment adherence, and social support influence treatment outcomes differently across delivery methods? Researchers will compare the teletherapy group (remote sessions via digital platforms) and the in-person therapy group (face-to-face sessions) to evaluate differences in symptom reduction, general health improvement, and moderating factors like therapeutic alliance. Participants will: * Undergo a 8-week intervention with weekly structured third-wave CBT sessions. * Complete assessments at baseline, post-intervention, and follow-up using validated scales (e.g., Generalized Anxiety Disorder-7 \[GAD-7\], Hamilton Anxiety Rating Scale \[HAM-A\]). * Engage in modules including mindfulness, behavioral activation, and exposure therapy, adapted for their assigned delivery method. This study aims to address gaps in mental health accessibility in Pakistan by evaluating whether teletherapy can serve as a viable alternative to traditional in-person care.
Trial Details
NCT Number NCT07119515
Lead Sponsor Government College University Faisalabad
Collaborators: Allied Hospital Faisalabad
Conditions Generalized Anxiety Disorder
Enrollment 25 participants
Start Date 2025-03-10
Primary Completion 2025-08-26 (estimated)
Study Completion 2025-08-26 (estimated)
Updated on ClinicalTrials.gov 2025-08-13